Rituximab-specific DNA aptamers are able to selectively recognize heat-treated antibodies.
The monoclonal anti-CD20 IgG1 antibody rituximab is used as a first-line treatment for B cell lymphoma. Like all therapeutic antibodies, it is a complex protein for which both safety and efficacy heavily depend on the integrity of its three-dimensional structure. Aptamers, short oligonucleotides wit...
Main Authors: | Michael Kohlberger, Sabrina Wildner, Christof Regl, Christian G Huber, Gabriele Gadermaier |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0241560 |
Similar Items
-
Simultaneous Monitoring of Monoclonal Antibody Variants by Strong Cation-Exchange Chromatography Hyphenated to Mass Spectrometry to Assess Quality Attributes of Rituximab-Based Biotherapeutics
by: Fiammetta Di Marco, et al.
Published: (2021-08-01) -
Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab
by: Sonia Boyer-Suavet, et al.
Published: (2020-01-01) -
DNA aptamer S11e recognizes fibrosarcoma and acts as a tumor suppressor
by: Yunyi Liu, et al.
Published: (2022-06-01) -
Development of anti-rituximab antibodies in rituximab-treated patients: Related parameters & consequences
by: Fatemeh Saffari, et al.
Published: (2022-01-01) -
Are female starlings able to recognize the scent of their offspring?
by: Luisa Amo, et al.
Published: (2014-01-01)